Literature DB >> 1277596

Uremic middle molecules.

J Bergström, P Fürst.   

Abstract

Mesh：

Substances：

Year:  1976        PMID： 1277596

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN： 0301-0430            Impact factor:   0.975


× No keyword cloud information.
  7 in total

1.  Haemoperfusion in the treatment of chronic renal failure in patients on haemodialysis.

Authors:  S I Ryabov; G D Shostka; B G Lukichev; V V Strelko; V N Spiridonov; N T Kartel; A B Scherbitsky
Journal:  Int Urol Nephrol       Date:  1984       Impact factor: 2.370

2.  Peritoneal dialysability of "uraemic substances".

Authors:  I Taraba; V Spustova; A Balás-Eltes; R Dzurik; G Y Petrányi
Journal:  Int Urol Nephrol       Date:  1981       Impact factor: 2.370

3.  Serum and ultradiafiltrate middle molecules in hemodialysed patients.

Authors:  P Bozek; J Erben; J Zahradnik; R Dzúrik
Journal:  Int Urol Nephrol       Date:  1979       Impact factor: 2.370

4.  End-stage renal disease and diabetes catalyze the formation of a pentose-derived crosslink from aging human collagen.

Authors:  D R Sell; V M Monnier
Journal:  J Clin Invest       Date:  1990-02       Impact factor: 14.808

5.  The effect of uraemic "middle-sized molecules" on T lymphocyte functions.

Authors:  K Kálmán; L Löcsey; M Hauck; A Leövey
Journal:  Int Urol Nephrol       Date:  1980       Impact factor: 2.370

6.  Prediction of radiographic severity of renal osteodystrophy by serum values.

Authors:  L E Guerra; J A Amato; M A Galen; J F Maher
Journal:  Int Urol Nephrol       Date:  1980       Impact factor: 2.370

7.  Differential effects of type 2 (non-insulin-dependent) diabetes mellitus on pentosidine formation in skin and glomerular basement membrane.

Authors:  D R Sell; E C Carlson; V M Monnier
Journal:  Diabetologia       Date:  1993-10       Impact factor: 10.122
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.